JP2015524807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524807A5 JP2015524807A5 JP2015524402A JP2015524402A JP2015524807A5 JP 2015524807 A5 JP2015524807 A5 JP 2015524807A5 JP 2015524402 A JP2015524402 A JP 2015524402A JP 2015524402 A JP2015524402 A JP 2015524402A JP 2015524807 A5 JP2015524807 A5 JP 2015524807A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675754P | 2012-07-25 | 2012-07-25 | |
| US61/675,754 | 2012-07-25 | ||
| PCT/US2013/051745 WO2014018570A1 (en) | 2012-07-25 | 2013-07-23 | Cystathionine-υ-lyase (cse) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524807A JP2015524807A (ja) | 2015-08-27 |
| JP2015524807A5 true JP2015524807A5 (enExample) | 2016-08-18 |
| JP6391071B2 JP6391071B2 (ja) | 2018-09-19 |
Family
ID=49997791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524402A Expired - Fee Related JP6391071B2 (ja) | 2012-07-25 | 2013-07-23 | シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9725426B2 (enExample) |
| EP (1) | EP2877457B1 (enExample) |
| JP (1) | JP6391071B2 (enExample) |
| KR (1) | KR20150041635A (enExample) |
| CN (1) | CN104662007B (enExample) |
| AR (1) | AR091857A1 (enExample) |
| AU (2) | AU2013293090A1 (enExample) |
| CA (1) | CA2879879C (enExample) |
| HK (1) | HK1210614A1 (enExample) |
| IN (1) | IN2015DN01161A (enExample) |
| RU (1) | RU2661879C2 (enExample) |
| TW (1) | TWI684583B (enExample) |
| WO (1) | WO2014018570A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9643942B2 (en) * | 2014-02-28 | 2017-05-09 | Zeon Corporation | Method for manufacturing 1,1-disubstituted hydrazine compound |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| BR112017000468A2 (pt) * | 2014-07-09 | 2017-11-07 | Sun Pharmaceutical Ind Ltd | forma de dosagem de cápsula de liberação prolongada |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| WO2016160885A1 (en) | 2015-03-30 | 2016-10-06 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and uses thereof |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11332438B2 (en) | 2017-12-01 | 2022-05-17 | Ultragenyx Pharmaceutical Inc. | Creatine prodrugs, compositions and methods of use thereof |
| US12667087B2 (en) | 2019-06-07 | 2026-06-30 | Agios Pharmaceuticals, Inc. | Methods of treatment with aminolevulinic acid synthase 2 (ALAS2) modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD13769A (enExample) * | ||||
| DE13769C (de) | W. H. MC. NARY in Brooklyn (Staat New-York, V. St. A.); Vertreter : F. E. THODE & KNOOP in Dresden, Augustusstrafse 3 II | Neuerungen an flachen Kettenstühlen | ||
| DE207626C (enExample) * | 1900-01-01 | |||
| NL6402073A (enExample) | 1963-03-05 | 1964-09-07 | ||
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| DD207626A3 (de) * | 1981-12-17 | 1984-03-07 | Manfred Just | Verfahren zur herstellung des 3-amino-5-hydrazino-1,2,4-triazols und dessen derivaten |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4610717A (en) * | 1985-11-26 | 1986-09-09 | Shell Oil Company | Certain 5-(R-oxy)-1-phenyl or (3-(trifluoromethyl)phenyl)triazoles, useful for controlling undesired plant growth |
| US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| EA200100972A1 (ru) * | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| WO2005103012A1 (ja) | 2004-04-21 | 2005-11-03 | Ono Pharmaceutical Co., Ltd. | ヒドラジノ複素環ニトリル化合物およびその用途 |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
-
2013
- 2013-07-22 AR ARP130102598A patent/AR091857A1/es unknown
- 2013-07-23 RU RU2015105700A patent/RU2661879C2/ru active
- 2013-07-23 JP JP2015524402A patent/JP6391071B2/ja not_active Expired - Fee Related
- 2013-07-23 HK HK15111386.2A patent/HK1210614A1/xx unknown
- 2013-07-23 KR KR1020157004422A patent/KR20150041635A/ko not_active Ceased
- 2013-07-23 AU AU2013293090A patent/AU2013293090A1/en not_active Abandoned
- 2013-07-23 US US14/416,596 patent/US9725426B2/en not_active Expired - Fee Related
- 2013-07-23 CA CA2879879A patent/CA2879879C/en not_active Expired - Fee Related
- 2013-07-23 WO PCT/US2013/051745 patent/WO2014018570A1/en not_active Ceased
- 2013-07-23 EP EP13823365.5A patent/EP2877457B1/en not_active Not-in-force
- 2013-07-23 CN CN201380049534.7A patent/CN104662007B/zh not_active Expired - Fee Related
- 2013-07-24 TW TW102126481A patent/TWI684583B/zh not_active IP Right Cessation
-
2015
- 2015-02-12 IN IN1161DEN2015 patent/IN2015DN01161A/en unknown
-
2017
- 2017-07-31 US US15/664,970 patent/US20170327478A1/en not_active Abandoned
-
2018
- 2018-01-25 AU AU2018200632A patent/AU2018200632B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015105700A (ru) | ИНГИБИТОРЫ ЦИСТАТИОНИН-γ-ЛИАЗЫ (CSE) | |
| RU2015105893A (ru) | Ингибиторы цистатионин-г-лиазы (cse) | |
| US10328072B2 (en) | Treatment of lung cancer using hedgehog pathway inhibitors | |
| US20210077500A1 (en) | Pikfyve inhibitors for cancer therapy | |
| JP2017526716A5 (enExample) | ||
| US10583129B2 (en) | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | |
| JP2017522352A5 (enExample) | ||
| JP2016531861A5 (enExample) | ||
| JP2013518882A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| WO2015008229A1 (en) | Autotaxin inhibitors | |
| JP2009040767A5 (enExample) | ||
| AU2012332111B2 (en) | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia | |
| JP2019516726A5 (enExample) | ||
| JP2018538241A5 (enExample) | ||
| JP2017525777A5 (enExample) | ||
| JP2018515507A5 (enExample) | ||
| JP2018504391A5 (enExample) | ||
| US20190365680A1 (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer | |
| EP3134398A1 (en) | Autotaxin inhibitors | |
| Zhang et al. | GW24-e3532 Effects of hydronephrosis on cardiac ACE/ACE2 gene expression in mice | |
| US20190365742A1 (en) | Azole treatment regimen with reduced hepatotoxicity |